Drug Profile
Photodynamic immunotherapy
Alternative Names: PDITLatest Information Update: 26 Mar 2003
Price :
$50
*
At a glance
- Originator Wound Healing of Oklahoma
- Developer Procept; Wound Healing of Oklahoma
- Class Antineoplastics
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Mar 2003 No development reported - Preclinical for Cancer in USA (Injection)
- 21 Feb 2000 Procept has merged with Heaven's Door Corporation to form HeavenlyDoor.com
- 21 Feb 2000 Pacific Pharmaceuticals is now called Procept and has the biotechnology assets of the former Procept